SOFWAVE MED Ltd

Sofwave reported Q4 2025 revenue of $28.9m (+58% year‑over‑year) and a record quarter; full‑year revenue was $87.6m (+47%). The company recorded an IFRS net profit of $5.5m and strong recurring revenue of $13.2m in the quarter (43% of revenue, +83%). Non‑IFRS operating income in Q4 was $4.6m (~16% of revenue); liquidity stood at $35.3m. Sofwave cites product innovations (liftHD Body, Pure Impact VIP) and increased demand from GLP‑1‑mediated patients as drivers for further growth, but gives no concrete guidance for 2026. » More on de.investing.com

Sofwave Medical reports Q4 2025 revenue up 58% to $28.9m; IFRS net income was $4.1m (net margin 14%) and adjusted operating income $4.6m. For full-year 2025 revenue rose to $87.6m (+47%) and recurring usage fees now account for 43% of revenue. The company expanded its product offering (including liftHD, Pure Impact VIP), sells systems in over 52 countries and had $35.3m in cash; the stock rose 7.02% after the results. » More on de.investing.com